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ess: leif.bjermer@med.Summary Modern treatment decision making in medicine is recommended to be
evidence based. In order to have a high grade of evidence, the studies should have
sufficient power, be randomized and double blinded. Moreover, the evaluation
parameters should be solid and reproducible. While there is a lot focus on primary
study design much less is focused on patient eligibility and to what extent the
patients included in a clinical trial are representative for the patients treated in
‘‘real life’’. By knowing the profile and action of the drug it is thus often possible to
design inclusion criteria’s that already from the start, with high probability, predict
the results. If you wish to prove that the addition of long-acting beta-2 agonist is
better that increasing the anti-inflammatory treatment you should select mild stable
and highly reversible patients. On the other hand, if you wish to prove that
increasing anti-inflammatory treatment is beneficial, you choose patients proven to
be steroid responsive and slightly under treated. Applying common inclusion and
exclusion criteria’s often render only a few percent of the patient population
eligible. This is often forgot, when the results from these strictly selected patient
populations are extrapolated into ‘‘evidence based’’ treatment recommendations
directed towards a much larger and less selected patient population. Thus when
evidence are graded, it is important also to consider to what extent the results are
extendable to a much larger ‘‘real life’’ patient population. Modern asthma
management must consider pathophysiological mechanisms that not necessarily are
reflected by lung function parameters. Demands from medical authorities as the
medical authorities in Europe (EMEA) asking for 15% reversibility of asthma study
patients,helps to conserve the imbalance between clinical trials and real life.
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
lu.se.Introduction
Modern treatment decision-making in medicine is
recommended to be evidence based. In a practical
sense it means that we should rely more on
randomised placebo-controlled trials, and less on
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Figure 1 Adapted from Bisgaard and Szefler.2 Prescrip-
tions of labelled (defined daily doses) standardised for
catchment population aged 5–14 years in Denmark. Only
prescriptions by primary-care physicians. Data accessed
August 24, 2005 on http://www.medstat.dk.
L. BjermerS18what is usually referred to as personal or clinical
experiences. The medical evidences are graded
according to the strength of evidence, with
evidence level A being a very strong recommenda-
tion based upon a large number of patients tested
in a randomised placebo-controlled manner, with
sufficient evaluation period and solid evaluation
parameters. Level D is more or less based upon
preliminary observations and expert opinions.1
It is of course necessary to act according to
available evidence and the opposite would be a
disaster. However, while we are focussing upon the
results of a clinical trial, it is equally important to
consider whether the patients included are repre-
sentative of the patient in front of me and that I am
about to treat. If we focus more on the results and
less on the inclusion criteria you may come up with
wrong treatment recommendations. This was ex-
cellently addressed in a recent letter by Bisgaard
and Szefler2 in The Lancet. While the use of long-
acting beta-2 agonists (LABAs) are well documen-
ted in adults, these results have in clinical practise
been extrapolated to children, even though the
evidence for effect in this group is ill documented.
In Denmark, since 2003 more children have been
treated with fixed combinations of fluticasone and
salmeterol (FP/SM), than by FP alone (Fig. 1),
potentially raising the risk of overtreatment of
LABAs, especially in mild asthmatic patients.
I hypothesise that by knowing the inclusion
criteria used for a clinical trial, it is also possible
to predict the results with a high degree ofprobability. This can be exemplified by a number
of clinical trials documented in the literature.Statement: ‘‘The addition of a long-
acting beta-2 agonist is better than
increasing the anti-inflammatory
treatment’’
If you wish to document that a bronchodilator is
better than increasing the anti-inflammatory treat-
ment, i.e. increasing the inhaled corticosteroid
(ICS) dose, you need to select patients according to
criteria that are likely to favour bronchodilation.
Several large multicentre studies have convincingly
shown that the addition of an LABA is better than
increasing (doubling) the dose of ICS. One recent
example is the comparison of a fixed combination
of FP and SM (FP/SM), compared to a higher dose of
FP.3 In this large multicentre study including 3421
patients, it was shown that FP/SM was slightly
superior to FP in achieving optimal clinical control;
this was true for all stages of severity. However, the
patients included in the study were already known
to be excellent beta-2 agonist responders with a
documented reversibility of over 25% after a short-
acting beta-2 agonist (SABA). In another study
comparing the addition of SM or montelukast (ML)
to a fixed dose of FP (FP/SM or FP/ML), FP/SM was
found to be superior to FP/ML giving better
symptom control and better improvement in lung
function.4 Also in that study the response to SABA
was excellent, with a reversibility of more than
20%. Interestingly, FP/SM has also been documen-
ted to be superior to FP in patients with mild
steroid-naı¨ve asthma. This is in contrast to the
combination of budesonide and formoterol (BUD/
FM), which was unable to show the same super-
iority.5 While BUD/FM improved FEV1 slightly when
compared to BUD, there was no difference in
exacerbation rates or symptom control. The reason
for this difference is probably not due to crucial
differences in pharmacological effects between
FP/SM and BUD/FM but rather due to differences
in degree of pre-study beta-2 agonist responsive-
ness. In the BUD/FM study, the pre-study reversi-
bility criterion was 12% improvement in FEV1 after
SABA or a PEF variability of X15%. The actual
reversibility is not written in the publication but is
assumed to be less than in the FP/SM trial, with a
pre-requested SABA reversibility of X15% (the
actual mean reversibility was 27–29%).
The conclusion from a clinical study is also highly
dependent on the choice of primary evaluation
parameters. This was clearly shown in a study
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Patients feasibility in asthma trials S19comparing triamcinolone (TCA) versus SM as con-
troller therapy in patients with mild-moderate
asthma.6 While monotherapy with TCA and SM
showed similar improvement of lung function and
reduced the need for SABA compared to placebo,
SM was clearly inferior in controlling underlying
inflammation (i.e. induced sputum eosinophils and
exhaled nitric oxide), and was also associated with
more exacerbations and treatment failures.6 Simi-
lar discrepancies can be noted when comparing ML
versus SM as add-on therapy to FP. While FP/SM was
found to be superior in improving lung function and
symptom control in patients with a pre-defined
excellent SABA response, in another study FP/ML
was shown to be superior to FP/SM in preventing
exacerbation-induced bronchoconstriction after
regular treatment.7Statement: ‘‘Increasing the anti-inflamma-
tory treatment is better, or at least as
good as, adding a long-acting beta-2
agonist’’
Airway inflammation is the underlying cause of
asthma symptoms. If you want to prove the
hypothesis that increasing anti-inflammatory treat-
ment is better or equally effective than adding an
long acting beta-2 agonist (LABA), you have to (1)
choose patients with highly likely insufficient
inflammatory control, and (2) choose the correct
evaluation parameters.Figure 2 Schematic illustration of the documentation
process for a clinical drug. In the proof of concept phase
very strict inclusion criteria are applied. The treatment
‘‘inclusion criteria’’ diminish considerably when the drug
is being registered and entering the market.Choosing patients with insufficient
inflammatory control
Data from the FACET (Formoterol And Corticoster-
oids Establishing Therapy) study were published in
1997.8 This was one of the first studies which
convincingly showed that the addition of an LABA
not only had a beneficial effect on lung function but
also protected from asthma exacerbations. One
major inclusion criterion was ‘‘insufficient clinical
control on ICS treatment alone’’. Moreover, during
the run-in all patients received a high daily dose of
BUD (1600 mg), and those who did reach sufficient
clinical stability were excluded. Thus, 262 of 1114
patients (24%) entering the run-in were excluded,
mainly due to insufficient steroid responsiveness.
The study results showed that the addition of FM to
each BUD step was beneficial. However, the data
also showed that increasing the BUD dose from 200
to 800 mg/day was clearly more beneficial than
adding FM, with a 41% decrease in severe exacer-bation rate compared to an 18% decrease when FM
was added.
The IMPACT (Investigation of Montelukast as
Partner Agent for Complementary Therapy) study
is another example showing that increasing anti-
inflammatory treatment may be as beneficial as
adding LABAs.9 This study included 1490 patients
with documented insufficient clinical control on FP
200 mg daily during a run-in period of 4 weeks. The
primary aim of the study was to see whether
the addition of ML was as good as adding SM. The
primary evaluation parameter in this study was, as
in the FACET trial, the number of severe asthma
exacerbations. The study concluded that the
addition of ML was as good as adding SM with a
similar decrease in the numbers of asthma exacer-
bations, nocturnal awakenings and improvement of
quality of life (QoL).Choosing the right evaluation parameter
Both the FACET and the IMPACT studies showed that
the addition of LABA resulted in a better lung
function measured as PEF and or FEV11. However,
this improvement was not associated with either
protection from exacerbations or improvement in
QoL.8–10 Thus, it is clear that lung function
improvement is not clearly related to other
important measures of asthma control. Other
important parameters related to asthma control
are bronchial hyper-responsiveness as well as
surrogate markers of inflammation. In the study
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Figure 3 From Herland et al.15 From 870 prospective patients 334 were regarded as having pure asthma without any
degree of COPD. Only 11 patients remained as eligible after commonly used asthma clinical trial inclusion criteria were
applied.
L. BjermerS20by Sont et al.,11 it was convincingly shown that the
use of bronchial hyper-responsiveness to metacho-
line was superior to symptoms and lung function as
a guiding instrument for adjusting steroid treat-
ment. Surrogate markers of inflammation have also
been used as a guidance instrument with similar
success. In the study by Green et al.,12 ICS
treatment was adjusted according to the degree
of inflammation estimated from the induced
sputum eosinophils and measured at regular inter-
vals. By using sputum eosinophils as a guiding
instrument, the number of asthma exacerbations
decreased significantly in parallel to an achieved
lower number of eosinophils in sputum. This could
be achieved, without increasing the total ICS dose
in the sputum group compared to the controls. In
another study, exhaled nitric oxide was used as a
guiding instrument in the treatment of patients
with chronic asthma.13 ICS dose adjustment made
in order to keep exhaled nitrous oxide (ENO) below
15 PPB resulted in fewer exacerbations despite a
lower total ICS dose used in the ENO-controlled
arm. If these surrogate markers of inflammation are
being used as monitoring instruments, then in-
creasing the dose of ICS seems to be superior to
adding LABA in patients with insufficient control on
low-to-medium doses of ICS.14How representative are clinical trial
asthma patients compared to a general
asthma population?
A clinical drug on its way to the market will need to
pass through a number of ‘‘needle eyes’’ before the
drug can be used on a larger patient population(Fig. 2). In early Phases I–II, very strict inclusion
criteria are used in order to prove the concept,
evaluate the therapeutic ratio and establish the
correct dose for future trials. In Phase III, the
inclusions are still very strict, and it is during this
phase that most clinical documentation is col-
lected. Phase III studies are also the sole basis for
evidence-based decision making. However, the
strength of evidence is linked to the degree of
representativeness, i.e. it must be possible to
extrapolate the results from concluded clinical
trials into the real life situation. This was investi-
gated in a recent study,15 928 prospective patients
with obstructive lung disease from three specialist
clinics and 6 GP centres were classified according to
clinical phenotype, use of medication, presence of
co-morbidity, treatment and smoking history. The
aim was to see how common a typical ‘‘trial asthma
patient’’ was compared to ‘‘real life’’ asthma
patient population. ‘‘Inclusion criteria’’ for suitable
clinical ‘‘trial asthma patient’’ were defined as (a)
Doctors diagnosed asthma without concomitant
COPD, (b) FEV1 between 50% and 85% of predicted
normal, (c) Proven reversibility of FEV1 of at least
12% during the last 12 months, (d) No smoking or if
a previous smoker a smoking history of less than
10 packs per year, (d) No significant co-morbidity
that theoretically could interfere with the treat-
ment. Of the 928 patients entered, 870 patients
were eligible but only 18 patients (2%) remained
when the selection criteria were applied. Finally, if
a patient is entered into a clinical trial evaluating
the impact of additional therapy, then one addi-
tional inclusion criterion should be evidence of
active uncontrolled disease. If this criterion is
added, then only 11 patients (1.3%) would remain
(Fig. 3).
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From fairly straightforward clinical trial inclusion
criteria, less than 2% of patients can be regarded as
eligible for inclusion in a clinical trial. Many clinical
trials have inclusion criteria that limit the eligible
study population even more. Thus, it is question-
able whether it is possible to extrapolate knowl-
edge gained from the results of such a strictly
selected patient study into the real life situation. A
further complicating factor is the requirements of
the medical authorities. Despite the poor associa-
tion between lung function measurements and
clinical asthma control, lung function parameters
are regarded as important by the medical autho-
rities, regulators and reimbursement boards. The
medical authorities in Europe (EMEA) are presently
demanding that asthma patients should have a FEV1
reversibility of at least 15% to be considered as real
asthma patients in clinical trials. This is certain to
preserve this imbalance between clinical trials and
real life. There is a need for recognition of the
contribution from large ‘‘outcomes research stu-
dies’’ which reflect real life more accurately. For
the future, it is important that every (randomised
controlled) clinical study is accompanied by a
statement, where responsible investigators argue
for how results are to be interpreted and extended
to the larger real life population.References
1. Recommendations for grading of evidence. Oxford Centre
for Evidence Based Medicine. http://www.cebm.net/levels_
of_evidence.asp#levels
2. Bisgaard H, Szefler S. Long-acting b2 agonists and paediatric
asthma. Lancet 2006;367(9507):286–8.
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ,
Pauwels RA, et al. Can guideline-defined asthma control be
achieved? The Gaining Optimal Asthma Control study. Am J
Respir Crit Care Med 2004;170(8):836–44.
4. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A,
Rickard K, et al. Fluticasone propionate/salmeterol combi-
nation provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin
Immunol 2000;106(6):1088–95.
5. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E,
Sandstrom T, Svensson K, et al. Low dose inhaled budesonide
and formoterol in mild persistent asthma: the OPTIMA
randomized trial. Am J Respir Crit Care Med 2001;164
(8, Part 1):1392–7.
6. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske
RF, Sorkness CA, et al. Long-acting beta2-agonist mono-
therapy vs. continued therapy with inhaled corticosteroids
in patients with persistent asthma: a randomized controlled
trial. JAMA 2001;285(20):2583–93.
7. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM,
Edelman JM. A comparison of the effects of oral montelukast
and inhaled salmeterol on response to rescue bronchodila-
tion after challenge. Respir Med 2004;98(11):1051–62.
8. Pauwels RA, Lo¨fdahl CG, Postma DS, Tattersfield AE, O’Byrne
P, Barnes PJ, et al. Effect of inhaled formoterol and
budesonide on exacerbations of asthma. Formoterol and
Corticosteroids Establishing Therapy (FACET) International
Study Group. N Engl J Med 1997;337(20):1405–11.
9. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP,
Haahtela T, et al. Montelukast and fluticasone compared
with salmeterol and fluticasone in protecting against asthma
exacerbation in adults: one year, double blind, randomised,
comparative trial. BMJ 2003;327:1–6.
10. Juniper EF, Svensson K, O’Byrne PM, Barnes PJ, Bauer CA,
Lo¨fdahl CG, et al. Asthma quality of life during 1 year of
treatment with budesonide with or without formoterol. Eur
Respir J 1999;14(5):1038–43.
11. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke
JP, Sterk PJ. Clinical control and histopathologic outcome of
asthma when using airway hyperresponsiveness as an
additional guide to long-term treatment. The AMPUL Study
Group. Am J Respir Crit Care Med 1999;159(4, Part 1):
1043–51.
12. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D,
Bradding P, et al. Asthma exacerbations and sputum
eosinophil counts: a randomised controlled trial. Lancet
2002;360(9347):1715–21.
13. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR.
Use of exhaled nitric oxide measurements to guide treat-
ment in chronic asthma. N Engl J Med 2005;352(21):
2163–73.
14. Currie GP, Bates CE, Lee DK, Jackson CM, Lipworth BJ.
Effects of fluticasone plus salmeterol versus twice the dose
of fluticasone in asthmatic patients. Eur J Clin Pharmacol
2003;59(1):11–5.
15. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How
representative are clinical study patients with asthma or
COPD for a larger ‘‘real life’’ population of patients with
obstructive lung disease? Respir Med 2005;99(1):11–9.
